These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A randomized trial of 48 hours of prophylactic cefotaxime versus single dose in transurethral prostatic surgery.
    Author: Hargreave TB, Gould JC, Kinninmonth AW, Jeffrey RR, Varma JS, Macintyre CC, Elton RA, Chisholm GD.
    Journal: J Antimicrob Chemother; 1984 Sep; 14 Suppl B():263-9. PubMed ID: 6094450.
    Abstract:
    A previous randomized trial from this department demonstrated that there was significant reduction in morbidity and post-operative bacteriuria when men undergoing transurethral prostatectomy were given a prophylactic perioperative regimen of 48 h of cefotaxime compared with a no treatment control group. In this paper we report the results of a new randomized trial to determine whether a single dose of cefotaxime given with the induction of anaesthesia would be of equal efficacy to the previous 48 h regimen. We also investigated the ward bacterial flora for cefotaxime resistance before and during the trial. The 48 h regimen was significantly superior to the single dose in terms of the number of men who developed post operative complications and there was also a small but significant reduction in post-operative hospital stay. Forty-eight hours of prophylaxis covers the normal time of post-operative urethral catheterization and this may explain our findings. There was no evidence of emergence of cefotaxime resistant strains.
    [Abstract] [Full Text] [Related] [New Search]